Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Background

Recent trials of ribociclib, a cyclin-dependent kinase inhibitor, have shown promising results in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer. This meta-analysis evaluates the efficacy and safety of combining ribociclib with endocrine therapy (ET) versus ET alone in this patient population.

Methodology

A comprehensive search of PubMed, Embase, CENTRAL, Scopus, and Web of Science (up to July 2024, no language restrictions) identified randomized controlled trials (RCTs) comparing endocrine therapy (ET) with and without ribociclib for HR+/HER2- breast cancer. Bias was assessed using Cochrane's Risk of Bias tool. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) and odds ratios (ORs) for Grade III +

SUBMITTER: Dhungana R 

PROVIDER: S-EPMC12717364 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature